Dynavax to Report Second Quarter 2021 Financial Results and Host Conference Call on August 4, 2021

Rhea-AI Summary

Dynavax Technologies Corporation (NASDAQ: DVAX) is set to report its second quarter 2021 financial results on August 4, 2021, following the close of U.S. markets. A conference call will occur the same day at 4:30 p.m. ET. The company, known for its HEPLISAV-B® Hepatitis B vaccine, continues to develop novel vaccines and adjuvants, including collaborations for COVID-19 and other significant vaccines. The live webcast will be available on their investors’ website, with replay options for 30 days.

Positive

• Upcoming financial results may provide insights into revenue from HEPLISAV-B®.
• Ongoing collaborations for COVID-19 and additional vaccines indicate potential growth.

Negative

• None.

EMERYVILLE, Calif., July 21, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Wednesday, August 4, 2021 at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.  Alternatively, participants may dial (866) 420-4066 (domestic) or (409) 217-8237 (international) and refer to conference ID 9970706.  A replay of the webcast will be available for 30 days following the live event.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:
Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content:https://www.prnewswire.com/news-releases/dynavax-to-report-second-quarter-2021-financial-results-and-host-conference-call-on-august-4-2021-301338367.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax report its second quarter 2021 financial results?

Dynavax will report its second quarter 2021 financial results on August 4, 2021.

What time is the Dynavax conference call scheduled?

The conference call is scheduled for August 4, 2021, at 4:30 p.m. ET.

How can I access the Dynavax Q2 2021 webcast?

The webcast can be accessed through the 'Events & Presentations' section on Dynavax's investors' website.

What is Dynavax's main product?

Dynavax's main product is HEPLISAV-B®, a Hepatitis B vaccine approved in the U.S. and EU.